Trial Profile
Impact of Docetaxel and Cabazitaxel on circulating neuroendocrine markers in castration resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2019
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Docetaxel (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms NEUTAX
- 16 Nov 2016 Status changed from active, no longer recruiting to completed.
- 27 Mar 2013 New trial record